ReviewPharmacological research2022

Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.

Nitasha Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.